MDMA-assisted psychotherapy

MDMA-assisted psychotherapy is a form of psychotherapy that involves the use of the drug 3,4-Methylenedioxymethamphetamine (MDMA) to assist in the therapeutic process. This approach is currently being researched for its potential to treat a variety of mental health conditions, including post-traumatic stress disorder (PTSD), anxiety, and depression.

History

The use of MDMA in psychotherapy has its roots in the 1970s and 1980s, when therapists began using the drug as a tool to facilitate empathy and introspection. However, the drug was classified as a Schedule I substance in 1985, which greatly limited its use in therapeutic settings.

Mechanism of Action

MDMA is a serotonin-releasing agent that increases the release of serotonin in the brain. This can lead to feelings of euphoria, increased empathy, and heightened introspection, which can be beneficial in a therapeutic setting. The drug also has effects on the norepinephrine and dopamine systems, which can lead to increased energy and focus.

Therapeutic Use

In MDMA-assisted psychotherapy, the drug is administered in a controlled setting under the supervision of a trained therapist. The patient is then guided through a series of therapeutic exercises designed to help them explore and process difficult emotions and experiences.

Research and Efficacy

Several studies have shown promising results for the use of MDMA-assisted psychotherapy in treating PTSD. A 2021 study published in Nature Medicine found that patients who received MDMA-assisted psychotherapy showed significantly greater reductions in PTSD symptoms compared to those who received placebo.

Risks and Side Effects

Like all drugs, MDMA carries risks and potential side effects. These can include nausea, anxiety, insomnia, and dehydration. There is also the risk of serotonin syndrome, a potentially life-threatening condition that can occur when there is too much serotonin in the brain.

Legal Status

As of 2021, MDMA is classified as a Schedule I substance in the United States, meaning it is illegal to manufacture, distribute, or possess. However, the Food and Drug Administration (FDA) has granted "breakthrough therapy" designation to MDMA-assisted psychotherapy for PTSD, which could potentially expedite its approval for medical use.

See Also

• Psychedelic therapy
• Psychedelic drugs in medicine
• Post-traumatic stress disorder

• 
  MDMA-assisted psychotherapy
• 
  Alexander Shulgin